CVS Health CorpCVSBUYJan 02, 2014Stock price when the opinion was issued
As of Jun 05, 2026. Market Open.
Bought at less than 10x earnings with recent dividend increase is good for share price appreciation. Recent M&A also good for investors. Will continue to own shares. Excellent management team and solid dividend. Weakness is sector creating opportunities to buyout competitors.
Price target was raised today. This peaked in 2020-1 then was hit with a lot of bad news, like doubts over Signify and Oak Street acquisitions. But that negative sentiment has reversed, like their Medicare Advantage stars rating has gone up, and the street sees profitability rising in their pharmacy benefits management system, based on a new model last month. Trades under a cheap PE and pays a 3% dividend. He targets over $100 in 12 months. Is underloved and over-owned.
Healthcare has lagged this year. They run a chain of pharmacies, Aetna health insurance, pharmacy management and recently bought Oak Health. The CEO is doing a great job, and shares are not expensive around 8.5x PE. They took one some debt to bought some companies, but once they integrated them, it will ramp up cash flow.
(Analysts’ price target is $87.45)
Just bought this recently in the $66 range. Feels the space has a lot of potential and likes this as well as Walgreens (WAG-N). After a very robust 2013, a lot of individual issues of good companies and good prospects are starting to hit normalized valuations, so not a lot of opportunity for multiple revisions. Within the healthcare space, there is a lot more here. Only trading at 14X earnings and we have an aging population. With broader insurance opportunities comes more activity on the back end of stores.